Uncategorized | Precision Medicine Policy Network

Category Archives: Uncategorized

Workshop on Implementation Challenges in Precision Medicine, Nov 4th, 2017

By | Uncategorized | No Comments

• Brenda Wilson (University of Ottawa)
• Anne-Marie Laberge (CHU Sainte-Justine, Montreal)

1. to advance the discussion about implementation science issues in precision medicine
2. to highlight the importance of ‘upstream’ evidence on validity and utility as the foundation for effective approaches to implementation
3. to identify strategies to integrate research conducted at different points in the precision medicine ‘pipeline’

The workshop is open to all interested in precision medicine and its effective integration in Canadian health care, including
• health services and policy researchers, particularly those with interest in implementation science
• health technology assessment researchers and analysts
• clinicians with an interest in precision medicine
• basic science researchers in precision medicine
• precision medicine research funding agencies, particularly Genome Canada and regional Genomes, CIHR
~No registration required~

1. Welcome, introductions, goals of the meeting 
2. Implementation science and precision medicine (Anne-Marie Laberge/Brenda Wilson)
3. How implementation issues are currently integrated into Genome Canada’s precision health large scale applied health projects (Anne-Marie Laberge)
4. Problems with the precision medicine ‘pipeline’ (Brenda Wilson)
5. Facilitated discussion: are these problems real, and how to begin to address them in the Canadian research context?

LOCATION: Pinnacle Hotel Harbourfront
Port of Singapore Meeting Room (3rd floor)
1133 West Hastings Street,
Vancouver, British Columbia
TIME: 1.30-4.00 pm

Refreshments will be served

June 2017 Workshop: Risk-sharing Models to Advance Payer Paradigms for Precision Medicines

By | Uncategorized | No Comments

Despite significant scientific advances in the development of precision health technologies and interventions (PHTI), many fail to advance to clinical and other applications due to deficiencies in (a) rigorous and efficient evidence development at the pre-clinical and clinical research phases; (b) capacity to navigate regulatory approval processes; (c) understanding of market-access pathways, including reimbursement/payer and/or adoption decision-making; and (d) understanding of the practical and cultural challenges posed by the implementation of potentially disruptive precision medicine in real-world contexts. Those precision medicines that have been translated to marketed products have created substantial financial, operational, and/or cultural challenges for regulators, payers, and health systems.

On June 27th to 29th, 2017, the Precision Medicine Policy Network and Paceomics will bring together international experts from Canada, the United Kingdom, Australia, Japan and the United States. These experts – representing regulatory agencies, reimbursement agencies, the insurance industry, health system data analytics, the biotechnology sector, investors, clinicians, and patient organizations – will explore and identify promising strategies that can support the timely, risk managed, and sustainable adoption of PHTIs.

The workshop will address key challenges for health care payers and developers in evaluating and funding precision medicines. Sessions will focus on:
(1) Price based solutions to the challenges faced by health care payers in managing market access for precision medicines, such as price discounts or volume price agreements;
(2) Research based solutions to the challenges faced by health care payers in managing market access for precision medicines, such as only-in-research and only-with-research schemes; and
(3) The use of routine data infrastructure to address the challenges faced by health care payers in using real-world evidence to manage reimbursement of precision medicines, such as post-market surveillance infrastructure.

Stay tuned! Outputs will include a summary of workshop discussion & conclusions, and a manuscript will be prepared for publication.

New course offered: Introduction to Cost Effectiveness Modeling

By | Uncategorized | No Comments

May 29 – June 2, 2017, University of Alberta
Faculty: Drs Richard Edlin, Claire Hulme, Christopher McCabe, and Michael Paulden
Details: HERE

This 5 day course is designed to equip individuals who have a basic understanding of cost effectiveness analysis with the skills required to build two types of decision analytic cost effectiveness models; decision trees and Markov models.

Designed and delivered by internationally recognized experts in cost effectiveness analyses, the course will combine focused pedagogic sessions with practical exercises to provide participants with hands-on experience of building the most commonly used types of cost effectiveness models, undertaking deterministic and probabilistic sensitivity analyses, Value of Information Analyses and producing a range of outputs to meet the requirements of reimbursement authorities in North America, Europe and Australasia.